| Literature DB >> 23487596 |
Mikołaj Piekarski1, Anna Jelin'ska, Kamil Szymczak.
Abstract
BACKGROUND: The use of a combination of different drugs in postoperative analgesia extends the time of analgesia, makes it more efficient and allows the use of lower drug doses, which leads to less risk of side effects and drug dependence. The aim of this study was to develop and validate an HPLC method to determine the stability of fentanyl citrate and bupivacaine hydrochloride mixtures in standard infusion solutions of 0.9% sodium chloride and 5% glucose.Entities:
Year: 2012 PMID: 23487596 PMCID: PMC3591257 DOI: 10.1136/ejhpharm-2012-000088
Source DB: PubMed Journal: Eur J Hosp Pharm ISSN: 2047-9956
Figure 1Comparison of mobile phases with different acetonitrile (ACN) concentrations.
Comparison of the influence of acetonitrile (ACN) concentration on chromatographic parameters
| Retention time | Peak symmetry | |||
|---|---|---|---|---|
| ACN concentration in the mobile phase | Bupivacaine | Fentanyl | Bupivacaine | Fentanyl |
| 20% | 13.32 | 26.61 | 4.76 | 2.17 |
| 25% | 11.83 | 20.86 | 4.21 | 1.96 |
| 30% | 10.42 | 16.26 | 3.51 | 1.73 |
| 35% | 10.36 | 15.98 | 3.34 | 1.66 |
Figure 2Comparison of different flow rates.
Comparison of the influence of flow rate on chromatographic parameters
| Retention time | Peak symmetry | |||
|---|---|---|---|---|
| Flow rate | Bupivacaine | Fentanyl | Bupivacaine | Fentanyl |
| 1.0 ml/min | 14.66 | 22.78 | 2.96 | 1.65 |
| 1.2 ml/min | 12.19 | 18.92 | 2.93 | 1.64 |
| 1.5 ml/min | 9.81 | 15.46 | 2.72 | 1.73 |
| 1.7 ml/min | 8.63 | 13.33 | 2.67 | 1.57 |
Influence of potassium chloride on chromatographic separation
| Retention time | Peak symmetry | |||
|---|---|---|---|---|
| Mobile phase | Bupivacaine | Fentanyl | Bupivacaine | Fentanyl |
| 30% ACN | 10.15 | 15.46 | 3.51 | 1.73 |
| 30% ACN with 0.08 g/l KCl | 9.77 | 15.10 | 3.38 | 1.70 |
ACN, acetonitrile.
Statistical parameters for linearity of bupivacaine hydrochloride and fentanyl citrate
| Bupivacaine hydrochloride | Fentanyl citrate |
|---|---|
| y=ax±b | y=ax±b |
| a±Δa=53134±0.521 | a±Δa=0.031±0.002 |
| b±Δb=0.015±0.065 | b±Δb=0.006±0.008 |
| Sa=0.246 | Sa=0.001 |
| Sb=0.030 | Sb=0.004 |
| Sy=0.040 | Sy=0.005 |
| Ta=216184 | Ta=43 313 |
| Tb=0.476 | Tb=1542 |
| R=0.9998 | R=0.9958 |
| y=ax | y=ax |
| a±Δa=53245±0.505 | a±Δa=0.033±0.001 |
| Sa=0.238 | Sa=0.001 |
| Sy=0.039 | Sy=0.005 |
| r=0.9998 | r=0.9958 |
S is SD and T is variance.
Method precision for bupivacaine hydrochloride and fentanyl citrate
| Bupivacaine hydrochloride | |
| Average | 6.2635 |
| Variance: s2 | 1.89×10–3 |
| SD: s | 0.04354 |
| Relative SD: Sy | 0.00695 |
| Coefficient of variation: Wz | 0.70% |
| Fentanyl citrate | |
| Average | 0.1666 |
| Variance: s2 | 8.63×10–6 |
| SD: s | 0.00294 |
| Relative SD: Sy | 0.01763 |
| Coefficient of variation: Wz | 1.76% |
Intermediate method precision for bupivacaine hydrochloride and fentanyl citrate
| Bupivacaine hydrochloride | |
| Average | 6.3284 |
| Variance: s2 | 6.27×10–3 |
| SD: s | 0.0792 |
| Relative SD: sy | 0.0125 |
| Coefficient of variation: Wz | 1.25% |
| Fentanyl citrate | |
| Average | 0.1665 |
| Variance: s2 | 6.38×10–6 |
| SD: s | 0.0025 |
| Relative SD: sy | 0.0152 |
| Coefficient of variation: Wz | 1.52% |
Validation parameters of the method for bupivacaine hydrochloride and fentanyl citrate
| Parameter | Bupivacaine | Fentanyl |
|---|---|---|
| Linearity range | 0.059–0.177 mg/ml | 2.5–7.25 μg/ml |
| LOD | 2.47×10–3 mg/ml | 0.5 μg/ml |
| LOQ | 7.5×10–3 mg/ml | 1.5 μg/ml |
| Repeatability | 0.70% | 1.76% |
| Intermediate precision | 1.25% | 1.52% |
| Percentage recovery | 99.02% | 104.53% |
LOD, limit of detection; LOQ, limit of quantification.
Stability of bupivacaine hydrochloride and fentanyl citrate in 0.9% NaCl, 25°C
| Sample | t (h) | PIS | PBup | Pfent | PBup/PIS | %B | Pfent/PIS | %F |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 888999 | 30473943 | 171402 | 342789 | 100.00% | 0.1928 | 100.00% |
| 2 | 1 | 870079 | 29416332 | 164967 | 338088 | 98.63% | 0.1896 | 98.34% |
| 3 | 6.5 | 785461 | 27937316 | 154065 | 355680 | 103.76% | 0.1961 | 101.73% |
| 4 | 23 | 862758 | 29865464 | 167883 | 346163 | 100.98% | 0.1946 | 100.93% |
| 5 | 32.5 | 544133 | 19132839 | 106660 | 351621 | 102.58% | 0.1960 | 101.67% |
| 6 | 47 | 889441 | 30055613 | 166951 | 337916 | 98.58% | 0.1877 | 97.35% |
| 7 | 51.5 | 605950 | 21098765 | 118155 | 348193 | 101.58% | 0.1950 | 101.13% |
| 8 | 72 | 881896 | 29663404 | 166695 | 336359 | 98.12% | 0.1890 | 98.04% |
| Bupivacaine hydrochloride | Fentanyl citrate | |||||||
| Average amount | 100.53% | 99.89% | ||||||
| SD | 2.05 | 1.75 | ||||||
Stability of bupivacaine hydrochloride and fentanyl citrate in 5% glucose, 25°C
| Sample | t (h) | PIS | PBup | Pfent | PBup/PIS | %B | Pfent/PIS | %F |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 927521 | 28908568 | 155979 | 3116756 | 100.00% | 0.1681 | 100.00% |
| 2 | 1 | 890054 | 28720334 | 150732 | 3226808 | 103.53% | 0.1693 | 100.70% |
| 3 | 6.5 | 808511 | 25436765 | 137987 | 3146125 | 100.94% | 0.1706 | 101.49% |
| 4 | 23 | 904547 | 28270820 | 156270 | 3125412 | 100.28% | 0.1727 | 102.73% |
| 5 | 24 | 909636 | 28961765 | 160160 | 3183885 | 102.15% | 0.1760 | 104.70% |
| 6 | 47 | 999233 | 30018765 | 164415 | 3004181 | 96.39% | 0.1645 | 97.84% |
| 7 | 48 | 898613 | 28241824 | 155028 | 3142824 | 100.84% | 0.1725 | 102.59% |
| 8 | 72 | 921833 | 28846309 | 155120 | 3129234 | 100.40% | 0.1682 | 100.06% |
| Bupivacaine hydrochloride | Fentanyl citrate | |||||||
| Average amount | 100.57% | 101.26% | ||||||
| SD | 2.05 | 2.10 | ||||||